Trial · NCT07214753
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
NCT07214753, Recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy. Trials, record NCT07214753. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07214753
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
- NCT number
- NCT07214753
- Status
- Recruiting
- Enrollment
- 335 participants, estimated
- Lead sponsor
- AstraZeneca
- Conditions
- Severe Eosinophilic Asthma
- Interventions
- benralizumab
- First posted
- 2025-10-09
- Last updated
- 2026-09-18
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition | 24 months | Number and percentage of patient who met the 4 remission criteria (complete or partial) at 12 months and maintained up to 24months |
| Secondary | Number and percentage of patients achieving the criteria for clinical remission | 3, 6, 12 and 24 months | Number and percentage of patient with the criteria for complete or partial remission according to the following criteria: No need to use OCS; Absence of asthma symptoms (ACT score from 20/25 to 25/25); Absence of asthma exacerbations; Stable lung function (FEV1 decline of no more than 100 mL). |
| Secondary | Rate of any and SA exacerbations | 3, 6, 12 and 24 months | annualized exacerbations rate |
| Secondary | Mean change in Asthma Control Test (ACT) score | 1, 3, 6, 12 and 24 months vs baseline | mean (SD) changes (min - max) overtime in ACT score |
| Secondary | Mean changes in Asthma Control Questionnaire (ACQ) score | 1, 3, 6, 12 and 24 months vs baseline | mean (SD) changes (min - max) overtime in ACQ score |
| Secondary | Mean change in FEV1 - pre-BD | 3, 6, 12 and 24 vs baseline | mean (SD) changes in FEV1 (L) overtime |
| Secondary | Mean changes in FEV1 - post-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FEV1 (L) post-BD |
| Secondary | Mean changes in FEV1 % predicted - pre-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FEV1 % predicted pre-BD |
| Secondary | Mean changes in FEV1 % predicted - post-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FEV1 % predicted post-BD |
| Secondary | Mean changes in FVC pre-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FVC (L) pre-BD |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07214753
GET https://conductscience.org/api/trials/v1/NCT07214753/registered